## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Trek Financial LLC Decreases Stock Holdings in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251205T134342 | Somewhat-Bullish | Relevance: 99%
-  Trek Financial LLC significantly reduced its stake in Merck & Co., Inc. by 62.3% in Q2, selling 11,161 shares and retaining 6,768 shares valued at $536,000. This comes as Merck reported strong Q2 earnings, beating estimates, setting robust FY2025 guidance, and increasing its quarterly dividend. Analyst opinions on Merck are mixed, with some upgrading to "buy" while the consensus remains "hold," indicating varied perspectives on its future performance despite the positive financial results.

**2. M Holdings Securities Inc. Boosts Stake in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251205T125118 | Bullish | Relevance: 99%
- M Holdings Securities Inc. significantly increased its stake in Merck & Co., Inc. by 55.7% in Q2, acquiring 16,814 shares to hold a total of 47,025 shares valued at approximately $3.72 million. This comes as Merck exceeded Q3 earnings and revenue estimates and announced a dividend increase to $0.85 per share quarterly, offering a 3.4% yield. Other institutional investors also adjusted their positions in the pharmaceutical giant, which recently saw an EVP sell a portion of his holdings.

**3. Scotiabank Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price**
- Source: MarketBeat | 20251204T204429 | Bullish | Relevance: 99%
-  Scotiabank has raised its price target for Merck & Co., Inc. (NYSE:MRK) from $105 to $120, maintaining a "sector outperform" rating and suggesting an 18.98% upside. Other analysts like Goldman Sachs and Wells Fargo have also increased their targets, yet the market largely holds a "Hold" consensus with an average target of $107.38. Merck surpassed Q3 earnings and revenue estimates, and institutional investors have adjusted their holdings.

**4. Beutel Goodman & Co Ltd. Acquires 679,339 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251205T084257 | Bullish | Relevance: 99%
-  Beutel Goodman & Co Ltd. significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 15.4% in the second quarter, valuing its holdings at $404,067,000 and making Merck its 13th-largest holding. This comes as Merck exceeded earnings expectations for the quarter with EPS of $2.58 and revenue of $17.28 billion, subsequently raising its quarterly dividend to $0.85 per share.

**5. Merck & Co., Inc. (NYSE:MRK) Shares Up 1.3% on Analyst Upgrade**
- Source: MarketBeat | 20251203T222335 | Bullish | Relevance: 99%
- Merck & Co., Inc. (NYSE:MRK) shares rose 1.3% following an upgrade from Goldman Sachs, which raised its price target from $92 to $120 and reiterated a "buy" rating. Analyst sentiment for Merck is largely positive, with a "Moderate Buy" consensus rating and an average price target of $107.82, fueled by recent strong quarterly earnings, increased FY2025 guidance, and a raised quarterly dividend. The article also details recent insider stock sales and institutional investor activity, highlighting an increase in institutional ownership.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $242.0B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.4 |
| Current P/E | 11.1 |
| YoY Growth | -2.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.2% to -3.7% (-4.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.73% (CS: 16) | Weak |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.176x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.72
- **Stop Loss:** $94.28 (5.5% risk)
- **Target:** $105.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $9,074.52
- **Portfolio %:** 9.07%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*